• Early cancer detection technology innovator AnPac Bio-Medical Science Co. Ltd. has been awarded 142 patents with 95 patents pending as part of its bid to revolutionize cancer screening protocols
• AnPac Bio’s proprietary technology screens for a variety of biophysical properties and analyzes the results to establish risk factors for tumor development before tumor cells begin circulating in the bloodstream
• AnPac Bio’s technology can be combined with the more extant tumor cell-detection technology to boost the screening’s effectiveness
• The international company, with operations in the US and China recently named an accomplished bio-medical executive, Dr. Sunil Pandit, as the CEO of its U.S. operations.

The US and China based cancer screening technology innovator AnPac Bio-Medical Science (NASDAQ: ANPC) is advancing its operations in the United States, announcing Aug. 17 that accomplished bio-medical scientist Dr. Sunil Pandit has been named the CEO of the company’s U.S. operations, AnPac Technology USA Co., Ltd. (or AnPac Bio US). 

Dr. Pandit will lead the company’s strategic efforts to increase adoption of AnPac Bio’s early cancer detection technology — the pioneering Cancer Differentiation Analysis (“CDA”) platform that is the company’s core product and a proven revenue generator. 

“AnPac Bio has been recognized for its innovation and leadership in the field of early cancer screening and detection,” Pandit stated in the news release announcing his appointment (https://ibn.fm/KSjtr). “I am confident that given AnPac Bio’s strong innovation and superiority of its novel cancer screening products, we will win customers and market share and become a top tier cancer screening and early detection company in the U.S. in the future.”

Blood sample-based cancer screenings generally target protein-based biomarkers, genomic signals, such as circulating tumor DNA (ct-DNA), circulating in the blood stream to determine if a cancer exists and is spreading. The novelty of AnPac Bio’s early detection technology is looking for signals to help it assess the risk of cancer occurring before a tumor has developed. In addition to CDA technology’s ability to detect early cancer risk, this technology also has unique advantages in detecting multiple cancer types and is highly cost effective. 

“Recent studies have shown that there is a correlation between certain biophysical properties, including acoustical, electrical, magnetic, nano-mechanical and optical properties, and cancer occurrence. These studies have revealed that biophysical properties could be important non-genetic aspects of the micro-environment regulating the balance between normal cell growth and carcinogenesis (cancerous growth), which may lead to cancer occurrence,” the company’s Prospectus Supplement filed with the U.S. Securities and Exchange Commission last month states (https://ibn.fm/GfDKx). 

“Our proprietary CDA device uses an integrated sensor system to detect certain biophysical signals in blood samples,” the supplement adds. “After collecting data on these signals, we use our CDA technology and proprietary algorithm to measure and analyze these signals at multiple biological levels (including the protein, cellular and molecular levels) and with multiple parameters (including the overall CDA value, the PTF value and the CTF value).”

PTF and CTF values refer to the Protein Tumor Factor and Cellular Tumor Factor data sets and is proprietary to Anpac Bio CDA technology. 

Patent applications for the apparatus and methods behind the CDA detection technology began about a decade ago and in 2015 the company performed its first commercial CDA-based test, with the capacity to screen for 16 different types of cancers using a multi-level, multi-parameter approach, well before its current competitors. The company now is able to detect the risk of 26 different cancer types with high sensitivity and specificity. In 2020, despite the global pandemic, the Company’s overall revenue increased by 89.1%, to $3.2 million. The company also pre-announced recently that its test volume in the first half of 2021 has increased 110% over the same period in 2020.

For more information, visit the company’s website at www.AnPacBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.